Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Viaskin PT
- Development stage
- Phase 1
- Lead developer
- DBV Technologies
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Epicutaneous, Transdermal, Topical
01
Overview
Viaskin PT is an investigational epicutaneous immunotherapy (EPIT) patch developed by DBV Technologies for the delivery of pertussis toxin antigen through intact skin. The technology is based on the proprietary Viaskin platform, which enables non-invasive administration of biologically active compounds to the immune system via the skin. The primary mechanism involves presenting pertussis toxin to immune cells in a controlled manner, aiming to induce a protective immune response without systemic exposure or injection. This approach is being explored as a booster vaccine strategy for whooping cough (pertussis), with early-stage clinical trials assessing safety and immunogenicity[8]. DBV Technologies has previously advanced similar EPIT patches for food allergies such as peanut and milk.
- Brand names
- Viaskin PT
- Other names
- Viaskin-PTViaskin Pertussis Toxin patch
Beyond the preview
Go deeper on Viaskin PT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Viaskin PT.